查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1445529

全球腦腫瘤市場評估：按藥物、療法、適應症、最終用戶、分銷管道和地區劃分的機會和預測（2017-2031）

Brain Cancer Market Assessment, By Drug, By Therapy, By Indication, By End-user, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 230 Pages | 商品交期: 3-5個工作天內

價格

全球腦瘤市場規模將從2023年的25.1億美元成長到2031年的53.9億美元，2024-2031年預測期間複合年增長率為10.03%，預計還會成長。

這種疾病在世界不同地區的盛行率正在增加，預計這將促進市場成長。

根據美國癌症協會估計，2023年美國將診斷出約25,400例惡性脊髓或腦腫瘤。 在這些確診病例中，預計確診病例為女性 10,980 例，男性 14,420 例。 據估計，約有 18,760 人死於脊髓和腦腫瘤。 對兒童和成人神經系統疾病的認識不斷提高，正在為市場創造利潤豐厚的成長機會。 增加腦腫瘤可能性的各種危險因子包括病毒、過敏原、感染、接觸 N-亞硝基化合物以及頭部外傷或癲癇發作。

擴大研發活動

針對脊髓和腦腫瘤的各種研究工作旨在減輕與有效治療相關的各種毒性作用，確定癌症的根本原因，並確定新的治療方法和遞送方法。它正在發揮作用。 例如，2023 年，德州大學達拉斯分校和德州大學西南醫學中心的一組研究人員開發了一種使用金奈米粒子跨血腦屏障輸送藥物的方法。 該技術在治療膠質母細胞瘤（一種常見的腦腫瘤）的臨床試驗中顯示出積極的結果。 這種藥物傳遞方法將金奈米粒子和靶向血管的藥物共同配製，並將其註入血液中。 在這個實驗中，紫杉醇被用作化療藥物來治療肺癌、卵巢癌和乳癌。

兒童和成人的發生率不斷上升

根據美國癌症協會的數據，脊髓腫瘤和腦腫瘤是兒童第二常見的癌症，約佔兒童癌症的四分之一。 幾乎四分之三被診斷出患有腦腫瘤的兒童在診斷後至少存活 5 年。 因此，正在進行各種研究來揭示抗癌藥物對兒童的影響，這進一步導致了腦腫瘤市場的成長。

本報告調查了全球腦腫瘤市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素分析。我們編制了案例研究、競爭格局、主要公司簡介等等。

目錄

第 1 章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第 4 章全球腦腫瘤市場展望

  • 市場規模/預測
  • 透過藥物
    • 卡莫司汀
    • 順鉑
    • 貝伐珠單抗
    • 替莫唑胺
    • 鈴鐺蒂凡
    • 其他
  • 依治療方法
    • 化療
    • 標靶治療
    • 免疫治療
    • 其他
  • 依指示
    • 腦下垂體瘤
    • 神經膠質瘤
    • 腦膜瘤
    • 其他
  • 按最終用戶
    • 醫院
    • 癌症中心
    • 診斷實驗室
  • 按分銷管道
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 各公司的市佔率

第 5 章全球腦腫瘤市場展望：按地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 6 章市場映射

  • 透過藥物
  • 依治療方法
  • 依指示
  • 按最終用戶
  • 按分銷管道
  • 按地區

第 7 章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 生長抑制因素（問題、限制因素）

第 9 章監理架構與創新

  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第 10 章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（5 家參與公司）

第 11 章價格分析

第 12 章案例研究

第 13 章主要公司展望

  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Johnson & Johnson Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Amgen Inc.
  • EpicentRx, Inc.
  • Siemens Healthineer

第 14 章策略建議

第 15 章關於我們公司/免責聲明

Product Code: MX11078

Global brain cancer market is projected to witness a CAGR of 10.03% during the forecast period 2024-2031, growing from USD 2.51 billion in 2023 to USD 5.39 billion in 2031F. The increasing prevalence of the disease in various regions across the globe is expected to boost the growth of the market.

As per the estimates of the American Cancer Society, approximately 25,400 malignant tumors of the spinal cord or brain have been diagnosed in the United States in 2023. Out of these diagnosed cases, 10,980 are expected to be diagnosed in females and 14,420 are expected to be diagnosed in males. It is estimated that roughly 18,760 people will die from spinal cord and brain tumors. The rising awareness about neurological diseases in both children and adults is providing lucrative growth opportunities to the market. The different risk factors that are attributed to an increased chance of developing brain tumors include exposure to viruses, allergens, infections, N-nitroso compounds, and head injuries and seizures.

Increasing efforts of various governments to combat the disease are supporting important research discoveries. Various governments are investing in researching new ways to treat, diagnose, and prevent brain cancer. For instance, the government of Canada is dedicated to the development of new treatment strategies by promoting scientific collaborations. The collaborations with organizations such as the Brain Tumor Foundation of Canada and the Brain Canada Foundation (BC) are aiding in maximizing the impact of research investments. A neurosurgeon-scientist at the University of Toronto and the University Health Network, with the help of brain cancer research funding was able to find new therapies for preventing high-risk surgical procedures and transform the clinical management of patients with brain tumors. Another partnership with the Canadian Cancer Society has united 10 research teams that aim at making life-changing breakthroughs in brain cancer.

Growing Research and Development Activities

The various research activities aimed at spinal cord and brain tumors are dedicated to reducing the different toxic effects associated with effective therapies, identifying the underlying cause of cancer, and determining novel treatments and delivery methods. For instance, in 2023, a team of researchers from the University of Texas at Dallas and UT Southwestern Medical Center developed a method to deliver medication through the blood-brain barrier, using gold nanoparticles. The technique showed positive results for the treatment of glioblastoma, a common form of brain cancer, in the clinical study. The drug delivery method relies on the co-delivery of medication with vessel-targeted gold nanoparticles, that are then injected into the bloodstream. In the experiment, paclitaxel was used by the researchers to conclude the chemotherapy drug for treating lung, ovarian, and breast cancers.

Increasing Prevalence of Disease in Both Children and Adults

According to the American Cancer Society, spinal cord and brain tumors are the second most common type of cancer in children. They account for approximately one out of four cases of cancer in children. Almost three out of four children diagnosed with brain tumors survive at least five years after receiving the diagnosis. Hence, various studies are being conducted to determine the effects of cancer-treating drugs on children, which is further leading to the brain cancer market growth.

For instance, the PIRATE study conducted by EpicentRx, Inc. aims to determine the side effects of RRx-001 in young adults and children when given together with temozolomide and irinotecan. The study aims to determine if the given combination is helpful for young adults and children with previously treated cancerous tumors.

North America is Expected to Account for Significant Market Share

North America is expected to dominate the market due to the growing prevalence of brain cancer in the United States and Canada and the increase in the emphasis on cancer research. According to the National Brain Tumor Society, approximately one million individuals are living with a brain tumor in America and 94,390 individuals are expected to receive a primary brain tumor diagnosis in 2023. The Canadian Cancer Society estimated that, in 2023, 3,200 Canadians will be diagnosed with spinal cord and brain cancer and nearly 2,500 Canadians will die amongst them. Due to the unique challenges presented by brain cancer, research and development activities are increasingly being conducted by various research institutions and market players. Currently, a study is being conducted by the University of Alabama in Birmingham to determine the safety and tolerability of novel gamma-delta T cell therapy for treating patients who recently received a diagnosis of glioblastoma.

Increasing Cases of Glioma Support Market Growth

According to the National Brain Tumor Society, glioblastoma accounts for 50.1% of all primary malignant brain tumors, and has more than 14,490 Americans, expected to receive a diagnosis of glioblastoma in 2023. According to an article published by researchers from MU School of Medicine and the University of Rochester, in May 2023, 6 out of every 100,000 people receive a diagnosis of glioma in the United States every year. Due to the increasing prevalence of glioma in different regions across the globe, research and development activities are increasing to find novel treatment solutions.

Various regulatory bodies such as the Food and Drug Administration (FDA) are providing fast-track designation to drugs that treat glioma. For instance, the FDA granted fast-track designation to the herpes simplex virus-1 (HSV-1) viral immunotherapy agent CAN-3110 as a treatment for enhancing the overall survival of patients suffering from recurrent high-grade glioma. Across all dosing levels, the findings supported the safety of CAN-3110 despite the presence of HSV1 ICP34.5 gene. CAN-3110 is a first in class oncolytic viral immunotherapy that is designed for targeting cancer cells expressing Nestin.

Hospital Pharmacies Expected to Witness Significant Growth

The longstanding trust associated with hospital pharmacies is bolstering the expansion of the segment. Drugs that are essential for treatment of brain tumor are prescribed after the receipt of diagnosis and often require hospital administration. Furthermore, the easy claim of health insurance policies across hospital pharmacies further encourages patients to purchase brain cancer-treating drugs from them. The convenience offered by hospital pharmacies coupled with the assurance of availability of quality products that are within the expiry period is further boosting the segment growth.

On the contrary, online pharmacies are anticipated to witness significant expansion over the forecast period. It is due to the availability of a wide range of benefits offered by online pharmacies including fast delivery and shipping, privacy, and discount codes and coupons. The increasing practice of purchasing medicines from legitimate and verified online pharmacies across developed countries is supporting the expansion of the segment.

Future Market Scenario (2024 - 2031F)

Increasing research and development activities and supportive government initiatives are expected to support the growth of the market over the forecast period.

In 2023, a research team at Brigham and Women's Hospital tested and developed a novel approach for assessing the working of antitumor drugs for different patients. The scientists developed drug releasing microdevices that were used for testing several drugs, however only one of them was administered to the patients. Conducting further studies will aid in determining the effectiveness of microdevices in personalized cancer treatments.

Several studies are underway to determine the effects of various drugs on both adults and children.

A study being conducted by the University of Alabama at Birmingham is expected to determine the safety and tolerability of novel gamma-delta T cell therapy for treating patients who recently received a diagnosis of glioblastoma, projected to conclude by December 2024.

Key Players Landscape and Outlook

Key participants in the brain cancer market include F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, EpicentRx, Inc., and Siemens Healthineer. The market is expected to witness significant growth owing to rising investments by major market players in research and development activities and strategic collaborations. In 2023, the partnership between Ever Fortune and medical equipment giants Siemens Healthineers and General Electric Company (GE) was announced. Following the collaboration with the medical equipment giants, Ever Fortune is expected to focus on its expansion in the Southeast Asian market and strengthen its cooperation with major companies.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Brain Cancer Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Drug
    • 4.2.1. Carmustine
    • 4.2.2. Cisplatin
    • 4.2.3. Bevacizumab
    • 4.2.4. Temozolomide
    • 4.2.5. Belzutifan
    • 4.2.6. Others
  • 4.3. By Therapy
    • 4.3.1. Chemotherapy
    • 4.3.2. Targeted Therapy
    • 4.3.3. Immunotherapy
    • 4.3.4. Others
  • 4.4. By Indication
    • 4.4.1. Pituitary
    • 4.4.2. Glioma
    • 4.4.3. Meningioma
    • 4.4.4. Others
  • 4.5. By End-user
    • 4.5.1. Hospitals
    • 4.5.2. Cancer Centers
    • 4.5.3. Diagnostic Laboratories
  • 4.6. By Distribution Channel
    • 4.6.1. Hospital Pharmacy
    • 4.6.2. Retail Pharmacy
    • 4.6.3. Online Pharmacy
  • 4.7. By Region
    • 4.7.1. North America
    • 4.7.2. South America
    • 4.7.3. Europe
    • 4.7.4. Asia-Pacific
    • 4.7.5. Middle East & Africa
  • 4.8. By Company Market Share (%), 2023

5. Global Brain Cancer Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Drug
      • 5.1.2.1. Carmustine
      • 5.1.2.2. Cisplatin
      • 5.1.2.3. Bevacizumab
      • 5.1.2.4. Temozolomide
      • 5.1.2.5. Belzutifan
      • 5.1.2.6. Others
    • 5.1.3. By Therapy
      • 5.1.3.1. Chemotherapy
      • 5.1.3.2. Targeted Therapy
      • 5.1.3.3. Immunotherapy
      • 5.1.3.4. Others
    • 5.1.4. By Indication
      • 5.1.4.1. Pituitary
      • 5.1.4.2. Glioma
      • 5.1.4.3. Meningioma
      • 5.1.4.4. Others
    • 5.1.5. By End-user
      • 5.1.5.1. Hospitals
      • 5.1.5.2. Cancer Centers
      • 5.1.5.3. Diagnostic Laboratories
    • 5.1.6. By Distribution Channel
      • 5.1.6.1. Hospital Pharmacy
      • 5.1.6.2. Retail Pharmacy
      • 5.1.6.3. Online Pharmacy
    • 5.1.7. United States*
      • 5.1.7.1. Market Size & Forecast
      • 5.1.7.1.1. By Value
      • 5.1.7.1.2. By Volume
      • 5.1.7.2. By Drug
      • 5.1.7.2.1. Carmustine
      • 5.1.7.2.2. Cisplatin
      • 5.1.7.2.3. Bevacizumab
      • 5.1.7.2.4. Temozolomide
      • 5.1.7.2.5. Belzutifan
      • 5.1.7.2.6. Others
      • 5.1.7.3. By Therapy
      • 5.1.7.3.1. Chemotherapy
      • 5.1.7.3.2. Targeted Therapy
      • 5.1.7.3.3. Immunotherapy
      • 5.1.7.3.4. Others
      • 5.1.7.4. By Indication
      • 5.1.7.4.1. Pituitary
      • 5.1.7.4.2. Glioma
      • 5.1.7.4.3. Meningioma
      • 5.1.7.4.4. Others
      • 5.1.7.5. By End-user
      • 5.1.7.5.1. Hospitals
      • 5.1.7.5.2. Cancer Centers
      • 5.1.7.5.3. Diagnostic Laboratories
      • 5.1.7.6. By Distribution Channel
      • 5.1.7.6.1. Hospital Pharmacy
      • 5.1.7.6.2. Retail Pharmacy
      • 5.1.7.6.3. Online Pharmacy
    • 5.1.8. Canada
    • 5.1.9. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Drug
  • 6.2. By Therapy
  • 6.3. By Indication
  • 6.4. By End-user
  • 6.5. By Distribution Channel
  • 6.6. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Patent Landscape
  • 9.2. Regulatory Approvals
  • 9.3. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Pfizer, Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. F. Hoffmann-La Roche Ltd.
  • 13.3. Bayer AG
  • 13.4. Bristol-Myers Squibb Company
  • 13.5. Novartis AG
  • 13.6. Johnson & Johnson Inc.
  • 13.7. Dr. Reddy's Laboratories Ltd.
  • 13.8. Amgen Inc.
  • 13.9. EpicentRx, Inc.
  • 13.10. Siemens Healthineer

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 4. Global Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 5. Global Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 6. Global Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 8. Global Brain Cancer Market Share (%), By Region, 2017-2031F
  • Figure 9. North America Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. North America Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 11. North America Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 12. North America Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 13. North America Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 14. North America Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 15. North America Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 16. North America Brain Cancer Market Share (%), By Country, 2017-2031F
  • Figure 17. United States Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 18. United States Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 19. United States Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 20. United States Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 21. United States Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 22. United States Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 23. United States Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 24. Canada Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 25. Canada Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 26. Canada Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 27. Canada Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 28. Canada Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 29. Canada Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 30. Canada Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 31. Mexico Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. Mexico Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 33. Mexico Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 34. Mexico Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 35. Mexico Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 36. Mexico Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 37. Mexico Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 38. Europe Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 39. Europe Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 40. Europe Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 41. Europe Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 42. Europe Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 43. Europe Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 44. Europe Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 45. Europe Brain Cancer Market Share (%), By Country, 2017-2031F
  • Figure 46. Germany Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Germany Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. Germany Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 49. Germany Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 50. Germany Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 51. Germany Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 52. Germany Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 53. France Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. France Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 55. France Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 56. France Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 57. France Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 58. France Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 59. France Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 60. Italy Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Italy Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 62. Italy Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 63. Italy Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 64. Italy Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 65. Italy Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 66. Italy Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 67. United Kingdom Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 68. United Kingdom Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 69. United Kingdom Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 70. United Kingdom Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 71. United Kingdom Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 72. United Kingdom Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 73. United Kingdom Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 74. Russia Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Russia Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 76. Russia Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 77. Russia Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 78. Russia Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 79. Russia Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 80. Russia Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 81. Netherlands Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Netherlands Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 83. Netherlands Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 84. Netherlands Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 85. Netherlands Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 86. Netherlands Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 87. Netherlands Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 88. Spain Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Spain Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Spain Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 91. Spain Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 92. Spain Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 93. Spain Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 94. Spain Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 95. Turkey Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Turkey Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 97. Turkey Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 98. Turkey Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 99. Turkey Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 100. Turkey Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 101. Turkey Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 102. Poland Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. Poland Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 104. Poland Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 105. Poland Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 106. Poland Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 107. Poland Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 108. Poland Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 109. South America Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. South America Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 111. South America Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 112. South America Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 113. South America Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 114. South America Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 115. South America Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 116. South America Brain Cancer Market Share (%), By Country, 2017-2031F
  • Figure 117. Brazil Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Brazil Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 119. Brazil Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 120. Brazil Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 121. Brazil Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 122. Brazil Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 123. Brazil Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 124. Argentina Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 125. Argentina Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 126. Argentina Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 127. Argentina Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 128. Argentina Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 129. Argentina Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 130. Argentina Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 131. Asia-Pacific Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Asia-Pacific Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 133. Asia-Pacific Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 134. Asia-Pacific Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 135. Asia-Pacific Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 136. Asia-Pacific Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 137. Asia- Pacific Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 138. Asia-Pacific Brain Cancer Market Share (%), By Country, 2017-2031F
  • Figure 139. India Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 140. India Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 141. India Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 142. India Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 143. India Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 144. India Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 145. India Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 146. China Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 147. China Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 148. China Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 149. China Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 150. China Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 151. China Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 152. China Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 153. Japan Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 154. Japan Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 155. Japan Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 156. Japan Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 157. Japan Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 158. Japan Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 159. Japan Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 160. Australia Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 161. Australia Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 162. Australia Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 163. Australia Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 164. Australia Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 165. Australia Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 166. Australia Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 167. Vietnam Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. Vietnam Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 169. Vietnam Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 170. Vietnam Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 171. Vietnam Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 172. Vietnam Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 173. Vietnam Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174. South Korea Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 175. South Korea Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 176. South Korea Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 177. South Korea Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 178. South Korea Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 179. South Korea Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 180. South Korea Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 181. Indonesia Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. Indonesia Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. Indonesia Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 184. Indonesia Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 185. Indonesia Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 186. Indonesia Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 187. Indonesia Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 188. Philippines Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 189. Philippines Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 190. Philippines Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 191. Philippines Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 192. Philippines Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 193. Philippines Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 194. Philippines Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 195. Middle East & Africa Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 196. Middle East & Africa Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 197. Middle East & Africa Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 198. Middle East & Africa Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 199. Middle East & Africa Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 200. Middle East & Africa Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 201. Middle East & Africa Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 202. Middle East & Africa Brain Cancer Market Share (%), By Country, 2017-2031F
  • Figure 203. Saudi Arabia Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 204. Saudi Arabia Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 205. Saudi Arabia Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 206. Saudi Arabia Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 207. Saudi Arabia Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 208. Saudi Arabia Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 209. Saudi Arabia Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 210. UAE Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 211. UAE Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 212. UAE Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 213. UAE Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 214. UAE Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 215. UAE Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 216. UAE Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 217. South Africa Brain Cancer Market, By Value, In USD Billion, 2017-2031F
  • Figure 218. South Africa Brain Cancer Market, By Volume, In Million Units, 2017-2031F
  • Figure 219. South Africa Brain Cancer Market Share (%), By Drug, 2017-2031F
  • Figure 220. South Africa Brain Cancer Market Share (%), By Therapy, 2017-2031F
  • Figure 221. South Africa Brain Cancer Market Share (%), By Indication, 2017-2031F
  • Figure 222. South Africa Brain Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 223. South Africa Brain Cancer Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 224. By Drug Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225. By Therapy Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023